- Home
- ARQT vs PACS Comparison
ARQT vs PACS Comparison
Compare ARQT & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- PACS
- Stock Information
- Founded
- ARQT 2016
- PACS 2013
- Country
- ARQT United States
- PACS United States
- Employees
- ARQT N/A
- PACS N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- PACS
- Sector
- ARQT Health Care
- PACS
- Exchange
- ARQT Nasdaq
- PACS Nasdaq
- Market Cap
- ARQT 2.1B
- PACS 2.0B
- IPO Year
- ARQT 2020
- PACS 2024
- Fundamental
- Price
- ARQT $16.93
- PACS $10.43
- Analyst Decision
- ARQT Strong Buy
- PACS Strong Buy
- Analyst Count
- ARQT 7
- PACS 5
- Target Price
- ARQT $19.00
- PACS $31.00
- AVG Volume (30 Days)
- ARQT 1.5M
- PACS 1.3M
- Earning Date
- ARQT 11-05-2025
- PACS 11-06-2025
- Dividend Yield
- ARQT N/A
- PACS N/A
- EPS Growth
- ARQT N/A
- PACS 82.80
- EPS
- ARQT N/A
- PACS 0.68
- Revenue
- ARQT $263,464,999.00
- PACS $3,558,953,000.00
- Revenue This Year
- ARQT $72.46
- PACS $28.62
- Revenue Next Year
- ARQT $32.00
- PACS $16.94
- P/E Ratio
- ARQT N/A
- PACS $15.30
- Revenue Growth
- ARQT 99.50
- PACS 205.08
- 52 Week Low
- ARQT $8.03
- PACS $7.50
- 52 Week High
- ARQT $18.15
- PACS $43.92
- Technical
- Relative Strength Index (RSI)
- ARQT 57.20
- PACS 47.16
- Support Level
- ARQT $15.13
- PACS $7.50
- Resistance Level
- ARQT $18.15
- PACS $10.17
- Average True Range (ATR)
- ARQT 0.67
- PACS 0.77
- MACD
- ARQT 0.08
- PACS -0.16
- Stochastic Oscillator
- ARQT 60.00
- PACS 64.81
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.